

Assessing the Current Role of Platelet Function Testing

Eugene Braunwald,* Dominick Angiolillo,[†] Eric Bates,[‡] Peter B. Berger,[§] Deepak Bhatt,^{||} Christopher P. Cannon,* Mark I. Furman,[¶] Paul Gurbel,** Alan D. Michelson,^{††} Eric Peterson,^{‡‡} Stephen Wiviott*

*TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; [†]Department of Internal Medicine, University of Florida College of Medicine, Jacksonville, Florida; [‡]Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; [§]Geisinger Center for Health Research, Danville, Pennsylvania; ^{||}Department of Cardiovascular Medicine, Cardiovascular Coordinating Center, Cleveland Clinic, Cleveland, Ohio; [¶]Cardiovascular Medicine, South Shore Hospital, South Weymouth, Massachusetts; **Department of Medicine, Sinai Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland; ^{††}Center for Platelet Function Studies, Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester, Massachusetts; ^{‡‡}Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA

Address for correspondence:

Eugene Braunwald
TIMI Study Group
Cardiovascular Division
Brigham and Women's Hospital
Department of Medicine
Harvard Medical School
350 Longwood Avenue
Boston, Massachusetts 02115, USA
ebraunwald@partners.org

ABSTRACT

In vitro platelet function tests are commonly applied in research and offer justification for using antiplatelet therapy. However, studies assessing the ability of standardized platelet function tests to predict patients' clinical response to aspirin or clopidogrel have generated contradictory results. At this time, there is no standardized definition for resistance to antiplatelet therapy, and the appropriate treatment of patients who are hyporesponsive to these agents is not known. Although such tests have a role in research, their place in guiding therapy remains to be established, and prospective trials are urgently needed. The ideal platelet function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable.

Key words: catheterization/diagnostic interventional <cardiac, acute coronary syndromes <ischemic heart disease, platelets, thrombosis/hypercoagulable states

Introduction

Tests of platelet function have been used in multiple ways in both clinical and research settings.^{1,2} They were first employed to screen patients for bleeding disorders, and then to predict the risks of procedural bleeding and thrombosis. More recently, with the advent of more targeted prohemostatic and antiplatelet therapies, platelet function tests have been used to assess medication effectiveness, both during drug development and in clinical situations.

For patients with cardiovascular disease (CVD), the major applications of platelet function tests include the prediction of clinical outcomes and the monitoring of antiplatelet therapy. The key question relating to these issues is whether standardized laboratory tests of platelet response to aspirin (ASA) or clopidogrel therapy are predictive of the patient's clinical response to these agents. This article discusses the currently available tests of platelet function, their advantages and drawbacks, and their relationship to clinical outcomes of antiplatelet therapy. Current guidelines for platelet function testing and suggestions for additional research are also discussed.

Current Platelet Function Tests

Table 1 details some of the characteristics of the most commonly used platelet function tests.^{3,4} The historical "gold standard" is turbidometric platelet aggregometry, which measures platelet coaggregation in platelet-rich plasma (Figure 1).⁵ Samples are exposed to an agonist, such as adenosine diphosphate (ADP) or arachidonic acid, and the increase in light transmittance resulting from platelet-platelet aggregation is measured. Its advantages are that it can be used to monitor ASA, thienopyridines, and platelet glycoprotein (GP) IIb/IIIa inhibitor therapy.³ Its disadvantages include the large sample volumes required, long processing times, and complex sample preparation. Impedance aggregometry (Figure 2) is conceptually similar to turbidometric platelet aggregometry, but, rather than light transmission, it measures the increase in electrical impedance across two precious metal wires that results from platelet coaggregation in response to an agonist.⁵ It has the same disadvantages as turbidometric platelet aggregometry, but it uses whole blood instead of platelet-rich plasma.³

Other aggregation tests include the VerifyNow test (Figure 3) (Acumetrics, San Diego, Calif., USA), a simple,

TABLE 1: Current clinical tests of platelet function

Test	Advantages	Drawbacks	Able to monitor:		
			ASA	Thieno-Pyridines	GP IIb/IIIa Inhibitors
Platelet–Platelet Aggregation					
Platelet aggregometry: Turbidometric	Historical “gold standard”	Variable reproducibility; expensive; large sample volume; sample preparation; time-consuming	Yes ^d	Yes ^{a,b}	Yes
Platelet aggregometry: Impedance	Whole-blood assay	Expensive; large sample volume; sample preparation; time-consuming	Yes ^d	Yes ^{ab}	Yes
VerifyNow	Simple; rapid; POC; small sample volume; no sample preparation; whole-blood assay	No instrument adjustment	Yes ^c	Yes ^d	Yes ^e
Plateletworks	Little sample preparation; whole-blood assay	Not well studied	Yes ^d	Yes ^b	Yes
Basis: Activation-dependent changes in platelet surface					
Platelet surface P-selectin, platelet surface activated GP IIb/IIIa, leukocyte-platelet aggregates	Low sample volume; whole-blood assay	Sample preparation; expensive; requires flow cytometer, experienced staff	Yes ^d	Yes ^b	Yes
Platelet contribution to clot shear elasticity					
Thromboelastogram	POC; whole-blood assay; platelet clot formation and clot lysis data	Limited studies	Yes ^d	Yes ^b	Yes
Shear-induced platelet adhesion					
Impact cone and plate(let) analyzer	Simple; rapid; POC; small sample volume; high shear; whole-blood assay	Not widely available	Yes ^d	Yes ^b	NR
Cessation of blood flow by platelet plug (for PFA, at high shear)					
PFA-100	Simple; rapid; small sample volume; no preparation; whole-blood assay	No instrument adjustment; depends on vWF, Hct	Yes	NR	NR
Activation-dependent signaling					
VASP phosphorylation	Low sample volume; whole-blood assay; P2Y ₁₂ -dependent	Sample preparation; expensive; requires flow cytometer, experienced staff	No	Yes	No
Activation-dependent release from platelets					
Serum thromboxane B ₂	COX-1–dependent	Indirect; not platelet-specific	Yes	No	No
Urinary 11-dehydro-thromboxane B ₂	COX-1–dependent	Indirect; not platelet-specific; depends on renal function	Yes	No	No
Adapted with permission from Michelson AD, et al. ⁴ <i>Abbreviations:</i> ASA = aspirin; COX = cyclooxygenase; GP = glycoprotein; Hct = hematocrit; NR = not recommended; PFA = platelet function analyzer; POC = point of care; VASP = vasodilator-stimulated phosphoprotein; vWF = von Willebrand factor; ^a With arachidonic acid; ^b With ADP; ^c With ASA cartridge; ^d With P2Y ₁₂ cartridge; ^e With TRAP cartridge.					

rapid, point-of-care method that has several other advantages: required sample volumes are small, it uses whole blood, and no pipetting is required.⁵ VerifyNow has been used to monitor the pharmacodynamic effects of the 3 main classes of antiplatelet therapies—ASA, thienopyridines, and GP IIb/IIIa inhibitors.

Other methods assess activation-dependent changes on the platelet surface. These tests include measurement of levels of platelet surface P-selectin, activated GP IIb/IIIa, and leukocyte–platelet aggregation. Their advantages include the small sample volumes required and the use of whole blood; disadvantages include complex sample preparation, the requirement for flow cytometry and experienced operators, and lack of commercial availability. They have been used to monitor the various classes of antiplatelet therapies.

The thromboelastogram (TEG) Platelet Mapping System (Figure 4) measures platelet contribution to clot strength.⁵ It is a point-of-care method that uses whole blood to assess platelet clot formation and clot-lysis data. It is able to monitor all 3 classes of antiplatelet therapies. However, it requires pipetting and has undergone only limited study. The Impact cone and plate(let) analyzer is a simple, rapid, point-of-care method that assesses shear-induced platelet adhesion.⁶ It uses whole blood, requires low-sample volumes, and needs no sample preparation. The drawbacks include the need for pipetting and lack of widespread availability. It is not recommended for monitoring of GP IIb/IIIa inhibitor therapy.

The Platelet Function Analyzer (PFA)-100 measures in vitro the cessation of high-shear blood flow by the platelet plug. It is a simple, rapid, point-of-care, whole blood method that requires low sample volumes and no sample preparation. Its disadvantages are that it is dependent on von Willebrand factor (vWF) and hematocrit levels and that it requires pipetting. It is not recommended for monitoring of thienopyridines.⁶

Vasodilator-stimulated phosphoprotein (VASP) phosphorylation measures activation-dependent platelet signaling. Its advantages include small required sample volumes, the use of whole blood, stability (allowing samples to be shipped to a remote laboratory), and dependency on the P2Y₁₂ receptor, the site of action for thienopyridines. Its disadvantages are that it requires complex sample preparation, flow cytometry, and experienced technicians, and cannot be used to monitor ASA or GP IIb/IIIa inhibitor treatment.⁶

The serum thromboxane B₂ level reflects its activation-dependent release from platelets. Its chief advantage is that it is dependent on cyclooxygenase (COX)-1, the specific enzyme inhibited by ASA. However, thromboxane B₂ levels may be influenced by prostaglandins produced by leukocyte-derived COX-2. Therefore, thromboxane B₂ is not entirely



Figure 1: Turbidometric platelet aggregometer. It measures the decrease in light transmittance that results from platelet coaggregation in platelet-rich plasma, when samples are exposed to an agonist such as ADP. Reproduced with permission from Harrison P et al.⁵

COX-1 or platelet specific. This indirect measure is not completely platelet-specific, however. These characteristics also apply to measurements of the ratio of the stable urinary metabolite of thromboxane B₂, 11-dehydro-thromboxane B₂ (UDTB) to creatinine. These tests cannot be used to monitor thienopyridines or GP IIb/IIIa inhibitor therapy.

The Relationship between Results of In Vitro Platelet Function Tests and Clinical Response to Antiplatelet Therapy

When reviewing studies that have reported a link between laboratory measures of platelet function and outcomes of antiplatelet therapy in patients with CVD, it is important to keep several cautions in mind. First, these studies have generally included small numbers of patients (resulting in relatively small numbers of events) and have been conducted at single centers, precluding definitive conclusions. There is an absence of serial measurements. The known bias toward publication of “positive” studies must also be considered. However, the concordance in reports should also be recognized. It may also be difficult to assess the relationship between in vitro platelet reactivity and clinical outcomes because of inter- and inpatient variability in platelet responses to agonists such as ADP.⁷ Patient non-compliance with study medication is also an important practical issue because a noncompliant patient’s platelets will appear not to respond well to the putative ingestion of the antiplatelet agent.

Aspirin: Eikelboom and colleagues studied whether hyporesponse to ASA treatment was related to the risk of cardiovascular events, in a substudy of the Heart Outcomes Prevention Evaluation (HOPE) secondary prevention trial.⁸ Baseline UDTB levels were compared among 488 patients



Figure 2: Impedance platelet aggregometer. It measures the increase in electrical impedance across two precious metal wires that results from platelet coaggregation in whole blood, when samples are exposed to an agonist such as ADP. Reproduced with permission from Harrison P et al.⁵

receiving ASA who had myocardial infarction (MI), stroke, or cardiovascular death over 5 years of follow-up and 488 sex- and age-matched control patients taking ASA who had no such event. The adjusted odds ratio (OR) for the composite endpoint was 1.8 times higher for patients in the upper quartile of UDTB level compared with patients in the lowest UDTB quartile ($p = 0.009$) (Figure 5). Similar patterns were shown for the component events of MI (adjusted OR, 2.0; $p = 0.006$) and cardiovascular death (adjusted OR, 3.5; $p < 0.001$), but not for stroke. Thus, elevated UDTB levels appeared to identify patients whose platelets responded suboptimally to ASA treatment in this study.

Gum and colleagues assessed the relationship between hyporesponse to ASA treatment and the composite incidence of death, MI, or stroke in 326 US patients with stable CVD.⁹ Hyporesponse was defined as mean platelet aggregation of $\geq 70\%$ in response to $10\mu\text{mol/L}$ ADP agonism and aggregation $\geq 20\%$ with 0.5 mg/mL arachidonic acid



Figure 3: The VerifyNow platelet aggregometer. Reprinted with permission from Harrison P et al.⁵



Figure 4: The Thromboelastogram (TEG) Platelet Mapping system. Reproduced with permission from Harrison P et al.⁵

stimulation. In all, 5.2% of patients showed hyporesponse to ASA. Of these patients, 24% reached the composite endpoint over a mean 1.8 years of follow-up versus only 10% of patients with a "normal" response ($p = 0.03$). However, the relationships between hyporesponse (whether a categorical or continuous variable) and component event rates were not statistically significant. Of note, these same investigators had previously shown that hyporesponse as defined above did not correlate well with hyporesponse as assessed by the PFA-100 test (defined as having a normal collagen and/or epinephrine closure time) in this population.¹⁰

Ohmori and colleagues assessed the relationship between platelet hyporesponse to ASA therapy and clinical outcomes in 136 patients with stable CVD.¹¹ They assessed platelet responses to collagen stimulation by both standard light-transmittance aggregometry and by light-scattering intensities with a PA-20 aggregation analyzer (reflecting small, medium, or large aggregates). Patients in the upper quartile of aggregation by light transmittance, or who had large aggregates, had a significantly and independently increased risk of MI, cerebrovascular infarction, or cardiovascular death at 12 months (hazard ratio [HR], 7.76; $p = 0.008$ for light transmittance aggregometry; HR, 7.98; $p = 0.007$ for large aggregates).

Chen and colleagues examined the relationship between serum markers of myonecrosis after nonurgent percutaneous coronary intervention (PCI) and hyporesponse to ASA therapy among 151 patients pretreated with clopidogrel.¹² Response to ASA was assessed by a commercially available, point-of-care assay, the VerifyNow Ultra Rapid Platelet Function Assay-ASA (RPFA-ASA). Hyporesponse to ASA was defined as an ASA reaction unit of ≥ 550 at baseline (before clopidogrel treatment and PCI) blood sampling. Myonecrosis was measured by creatine kinase-myocardial band (CK-MB) and troponin I (TnI) elevations after PCI. In all, 19.2% of the patients were hyporesponsive to ASA, and significantly more of these patients were women. After clopidogrel treatment and PCI, 51.7% of the ASA-hyporesponsive patients showed elevated CK-MB levels compared with 24.6% of the ASA-responsive patients ($p = 0.006$); 65.5% and 38.5% of patients, respectively, showed elevations in TnI

levels ($p = 0.012$). Hyporesponse to ASA was one of two independent predictors of CK-MB elevation after PCI in multivariable analysis (OR, 2.9; $p = 0.015$). Thus, despite adequate pretreatment with clopidogrel, patients with a lesser response to ASA treatment in this study remained at increased risk of myonecrosis after PCI.

Clopidogrel: Matetzky and colleagues examined the relationship between hyporesponse to clopidogrel treatment and clinical outcomes in 60 consecutive patients with MI undergoing primary PCI with stenting at one center.¹³ All received clopidogrel, ASA, and eptifibatid. Controls were 10 consecutive patients undergoing primary PCI alone who received no clopidogrel. Platelet aggregation was assessed by cone and plate(let) analysis and aggregation responses to $5\mu\text{mol/L}$ ADP and $10\mu\text{mol/L}$ epinephrine. Patients were first grouped into quartiles by percent reduction in ADP-induced aggregation from baseline to Day 6; values ranged from 103% of the baseline value in the first quartile (clopidogrel hyporesponse; $n = 15$) to 33% of the baseline value in the fourth quartile ($p < 0.01$ across groups). Similar patterns were shown for epinephrine-induced aggregation and the cone and plate(let) analysis. Patients in the clopidogrel-hyporesponse group experienced 7 of the 8 major cardiac events that occurred during the 6-month follow-up. In all, 40% of these patients had another ischemic event, whereas 13% of patients in the fourth quartile had major bleeding. Angiographic findings and infarct size were not different across groups. Of note, patients with

recurrent events were older and had a higher Killip class at presentation, and the analysis did not adjust for these or other risk factors. The investigators did not report data regarding a correlation between cone and plate(let) analysis and clinical outcomes.

Gurbel and colleagues used VASP phosphorylation to examine the relationship between platelet reactivity to clopidogrel treatment and stent thrombosis.¹⁴ They compared platelet reactivity to ADP and P2Y₁₂ activity in 20 patients who developed subacute stent thrombosis after clopidogrel therapy versus that of 100 age-matched controls. Both measures were significantly increased in patients with thrombosis, but there was substantial overlap in values between groups. Of note, patients with $<40\%$ aggregation had no stent thrombosis, representing a possible threshold effect. Other investigators have reported a relationship between incomplete P2Y₁₂ receptor blockade by clopidogrel as assessed by VASP phosphorylation and stent thrombosis and greater shear-induced platelet aggregation in patients with stent thrombosis compared with thrombosis-free patients or volunteers.^{15,16}

Finally, Wenaweser and colleagues have studied the relative associations between ASA and clopidogrel hyporesponse and subacute stent thrombosis.¹⁷ They compared 23 patients with previous stent thrombosis (median, 7 days after implantation) at 1 center with 50 patients who had undergone stenting without developing thrombosis and with 9 healthy volunteers. Platelet aggregation in response to 5 and $20\mu\text{mol/L}$ ADP was assessed via optical aggregometry during 1 month of ASA monotherapy and during a second month of combined ASA and clopidogrel treatment (after a 300 mg loading dose of clopidogrel). Maximal platelet aggregation was significantly higher in patients with stent thrombosis than in controls or volunteers. Hyporesponse to ASA, defined as $>20\%$ aggregation in response to 0.5 mg/mL arachidonic acid, was more common in patients with stent thrombosis (48%) than in control patients (32%, $p = \text{NS}$) or volunteers (0%, $p = 0.01$). Hyporesponse to clopidogrel, defined as a less than 10% relative change in aggregation, did not differ significantly among groups (4% of patients with stent thrombosis, 6% of control patients, and 11% of the volunteers, respectively, all $p = \text{NS}$). Hyporesponse to both ASA and clopidogrel, however, was more common in patients with stent thrombosis (52%) than in controls (38%, $p = \text{NS}$) or volunteers (11%, $p < 0.05$). The investigators concluded that hyporesponse to ASA, but not to clopidogrel may be associated with a risk of thrombosis after stenting.




Figure 5: Risk of myocardial infarction, stroke, or cardiovascular death by quartile of urinary 11-dehydro-thromboxane B₂ level among patients in a substudy of the HOPE secondary prevention trial of ASA. Adapted with permission from Eikelboom JW et al.⁸

Current Role of Platelet Reactivity Testing

According to the most recent consensus statement on the use of antiplatelet agents and position paper on ASA “resistance” from the International Society on Thrombosis

and Haemostasis, it is currently not recommended to test patients for ASA or clopidogrel resistance outside of clinical trials or to change therapy based on such testing.^{18,19} There are two main reasons for these recommendations. First, a clinically meaningful, standardized definition of resistance based on data linking therapy-dependent laboratory tests to clinical outcomes has yet to be developed.¹⁹ Second, the correct treatment of patients whose platelets are hyporesponsive to antiplatelet agents is unknown, given that no study has assessed clinical effectiveness after altering therapy based on laboratory findings of hyporesponse.¹⁹

The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions guidelines recommend daily ASA therapy after PCI for patients without ASA “resistance,” but no definition of resistance is offered.²⁰ For clopidogrel, the guidelines state that “. . .in patients in whom stent thrombosis may be catastrophic or lethal. . . platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated.” This is a Class IIb, level C recommendation, indicating that there is disagreement over whether the intervention is considered beneficial, and that the recommendation reflects only consensus opinion, not data from randomized clinical trials. Finally, the method to assess platelet inhibition is not described.

Adequately powered clinical trials are urgently needed to address 3 pivotal questions. First, which simple, inexpensive, and rapid test of platelet function (or combination of tests) best predicts clinical outcomes of antiplatelet therapy for specific patient subgroups? Second, are individual outcomes affected when treatment is changed in response to the test(s) results? The goal here would be development of thresholds for test results, similar to the practice of adjusting warfarin therapy by international normalized ratio (INR) results.^{21,22} Third, what is the benefit of dose titration or supplementary treatment with an agent having a different mechanism of action in patients with known hyporesponse to antiplatelet agents? For example, if a patient with CVD suffers an event while already taking ASA, is it more effective to increase the dose of ASA, add a thienopyridine for additional secondary prevention, or both, rather than to simply substitute the thienopyridine for ASA? Recent reports of early and late thrombosis of drug-eluting stents after interruption of antiplatelet therapy have raised concern about stopping antiplatelet therapy altogether after an acute cardiovascular event, but there are few data to guide clinicians in this regard.^{23–25} Clinical trials can provide the robust evidence needed to answer these questions, which are so important to clinicians.

Conclusions

Tests of platelet function in vitro are widely used in research and provide a mechanistic rationale for antiplatelet therapy. Correlating the results of such tests with clinical outcomes and using the results to guide therapy, however, remain challenging goals. The ideal test of platelet function for use in clinical practice would be rapid, easy-to-use, inexpensive, and would be a reliable indicator of the clinical response to the specific antiplatelet therapy or combination of therapies. Prospective clinical trials are now needed.

References

1. Michelson AD: Evaluation of platelet function by flow cytometry. *Pathophysiol Haemost Thromb* 2006;35:67–82
2. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1822–1834
3. Michelson AD: Platelet function testing in cardiovascular diseases. *Circulation* 2004;110:e489–e493
4. Michelson AD, Frelinger AL III, Furman MI: Current options in platelet function testing. *Am J Cardiol* 2006;98:S4–S10
5. Harrison P, Keeling D: Clinical tests of platelet function. In: Michelson AD, ed. *Platelets*. 2nd ed. Elsevier, Inc./Academic Press; San Diego, CA: 2007; 445–474
6. Michelson AD, Frelinger AL III, Furman MI: Current options in platelet function testing. *Am J Cardiol* 2006;98(10A): 4N–10N
7. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, et al.: Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. *J Thromb Haemost* 2007;5:75–81
8. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation* 2002;105: 1650–1655
9. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003;41:961–965
10. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol* 2001;88:230–235
11. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, et al.: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. *J Thromb Haemost* 2006;4:1271–1278
12. Chen WH, Lee PY, Ng W, Tse HF, Lau CP, et al.: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol* 2004;43:1122–1126
13. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 2004;109:3171–3175
14. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, et al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. *J Am Coll Cardiol* 2005;46:1827–1832

15. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv* 2003;59:295–302
16. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, et al.: Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. *J Am Coll Cardiol* 2005;45:1753–1756
17. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, et al.: Stent thrombosis is associated with an impaired response to antiplatelet therapy. *J Am Coll Cardiol* 2005;45:1748–1752
18. Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology: Expert consensus document on the use of antiplatelet agents. *Eur Heart J* 2004;25:166–181
19. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, et al, For the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. *J Thromb Haemost* 2005;3:1309–1311
20. American College of Cardiology/American Heart Association Task Force on Practice Guidelines: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. *Circulation* 2006;113:e1–e121
21. Gurbel PA: The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. *Rev Cardiovasc Med* 2007;7:S20–S28
22. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1822–1834
23. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;293:2126–2130
24. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet* 2004;364:1519–1521
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al.: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol* 2006;48:193–202